Tissue-type plasminogen activator: a historical perspective and personal account - PubMed (original) (raw)

Review

Tissue-type plasminogen activator: a historical perspective and personal account

D Collen et al. J Thromb Haemost. 2004 Apr.

Free article

Abstract

Over the past two decades tissue-type plasminogen activator (t-PA), the main physiological plasminogen activator, has been developed as a fibrin-specific thrombolytic agent for the treatment of various thromboembolic diseases. Milestones in this development include: first purification of human t-PA from uterine tissue, elucidation of the interactions regulating physiological fibrinolysis, thus providing a molecular basis for the concept of fibrin-specific plasminogen activation, first animal models of thrombosis and pilot studies in patients supporting the therapeutic potential of t-PA, cloning and expression of recombinant t-PA providing sufficient amounts for large scale clinical use, and demonstration of its therapeutic benefit in large multicenter clinical trials, mainly in patients with acute myocardial infarction (AMI), but also in patients with massive pulmonary embolism, ischemic stroke, deep vein thrombosis and peripheral arterial occlusion. Genetically modified variants of t-PA have been developed for bolus administration in patients with AMI.

PubMed Disclaimer

Similar articles

• The tissue-type plasminogen activator story.
  Collen D, Lijnen HR. Collen D, et al. Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1151-5. doi: 10.1161/ATVBAHA.108.179655. Arterioscler Thromb Vasc Biol. 2009. PMID: 19605778
• New developments in thrombolytic therapy.
  Collen D, Gold HK. Collen D, et al. Adv Exp Med Biol. 1990;281:333-54. Adv Exp Med Biol. 1990. PMID: 2129372 Review.
• [t-PA in thrombolytic therapy of acute myocardial infarct].
  Rutsch W, Schmutzler H. Rutsch W, et al. Herz. 1994 Dec;19(6):336-52. Herz. 1994. PMID: 7843690 Review. German.
• New developments in thrombolytic therapy.
  Collen DC, Gold HK. Collen DC, et al. Thromb Res Suppl. 1990;10:105-31. doi: 10.1016/0049-3848(90)90384-o. Thromb Res Suppl. 1990. PMID: 2180114 Review.

Cited by

• Tenecteplase for Acute Ischemic Stroke Thrombolysis: Practical Considerations and Real-World Implementation.
  Streib C. Streib C. Neurol Clin Pract. 2024 Feb;14(1):e200221. doi: 10.1212/CPJ.0000000000200221. Epub 2024 Jan 11. Neurol Clin Pract. 2024. PMID: 38223783
• An Echogenic Clot Method for Thrombolysis Monitoring in Thrombotic Stroke Models.
  Carter DE, Peng T, Moody MR, Huang SL, McPherson DD, Klegerman ME. Carter DE, et al. Med Res Arch. 2023 Mar;11(3):3702. doi: 10.18103/mra.v11i3.3702. Med Res Arch. 2023. PMID: 38046446 Free PMC article.
• Tissue-type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease.
  Tao Y, Ma J, Feng Y, Gao C, Wu T, Xia Y, Cheng Z, Zhang Y, Liu T, Hu Y, Tang LV. Tao Y, et al. MedComm (2020). 2023 Oct 5;4(5):e392. doi: 10.1002/mco2.392. eCollection 2023 Oct. MedComm (2020). 2023. PMID: 37808270 Free PMC article.
• The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator.
  Babenko VA, Fedulova KS, Silachev DN, Rahimi-Moghaddam P, Kalyuzhnaya YN, Demyanenko SV, Plotnikov EY. Babenko VA, et al. J Pers Med. 2023 Jul 23;13(7):1175. doi: 10.3390/jpm13071175. J Pers Med. 2023. PMID: 37511788 Free PMC article. Review.
• Enhanced Expression of Plasminogen Activators and Inhibitor in the Healing of Tympanic Membrane Perforation in Rats.
  Makuszewska M, Cieślińska M, Winnicka MM, Skotnicka B, Niemczyk K, Bonda T. Makuszewska M, et al. J Assoc Res Otolaryngol. 2023 Apr;24(2):159-170. doi: 10.1007/s10162-023-00891-5. Epub 2023 Feb 21. J Assoc Res Otolaryngol. 2023. PMID: 36810718 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Miscellaneous

  • NCI CPTAC Assay Portal